Tissue Inhibitor of Metalloproteinase-2
"Tissue Inhibitor of Metalloproteinase-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the family of TISSUE INHIBITOR OF METALLOPROTEINASES. It is a 21-kDa nonglycosylated protein found in tissue fluid and is secreted as a complex with progelatinase A by human fibroblast and uncomplexed from alveolar macrophages. An overexpression of TIMP-2 has been shown to inhibit invasive and metastatic activity of tumor cells and decrease tumor growth in vivo.
| Descriptor ID |
D019716
|
| MeSH Number(s) |
D12.776.645.875.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tissue Inhibitor of Metalloproteinase-2".
Below are MeSH descriptors whose meaning is more specific than "Tissue Inhibitor of Metalloproteinase-2".
This graph shows the total number of publications written about "Tissue Inhibitor of Metalloproteinase-2" by people in this website by year, and whether "Tissue Inhibitor of Metalloproteinase-2" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 2 | 3 | 5 |
| 1999 | 4 | 1 | 5 |
| 2000 | 4 | 0 | 4 |
| 2001 | 0 | 2 | 2 |
| 2002 | 3 | 2 | 5 |
| 2003 | 3 | 2 | 5 |
| 2004 | 3 | 1 | 4 |
| 2005 | 3 | 2 | 5 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 1 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 3 | 6 |
| 2015 | 2 | 3 | 5 |
| 2016 | 6 | 1 | 7 |
| 2018 | 1 | 1 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 3 | 4 |
Below are the most recent publications written about "Tissue Inhibitor of Metalloproteinase-2" by people in Profiles.
-
Characterising acute kidney injury: The complementary roles of biomarkers of renal stress and renal function. J Crit Care. 2022 10; 71:154066.
-
Utility of Biomarkers for Sepsis-Associated Acute Kidney Injury Staging. JAMA Netw Open. 2022 05 02; 5(5):e2212709.
-
APOL1 Kidney Risk Variants and Proteomics. Clin J Am Soc Nephrol. 2022 05; 17(5):684-692.
-
A genetic investigation of equine recurrent uveitis in the Icelandic horse breed. Anim Genet. 2022 Jun; 53(3):436-440.
-
Use of Biomarkers to Identify Acute Kidney Injury to Help Detect Sepsis in Patients With Infection. Crit Care Med. 2021 04 01; 49(4):e360-e368.
-
Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease. Rev Port Cardiol (Engl Ed). 2020 Nov; 39(11):667-672.
-
Effect of High Intensity Interval Training on Matrix Metalloproteinases in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy. Sci Rep. 2020 04 03; 10(1):5839.
-
The effect of frequent hemodialysis on matrix metalloproteinases, their tissue inhibitors, and FGF23: Implications for blood pressure and left ventricular mass modification in the Frequent Hemodialysis Network trials. Hemodial Int. 2020 04; 24(2):162-174.
-
Serial Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 and the Prognosis for Acute Kidney Injury over the Course of Critical Illness. Cardiorenal Med. 2019; 9(6):358-369.
-
Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury. Crit Care Med. 2019 10; 47(10):e820-e826.